ELVN-002 + trastuzumab + eribulin

ELVN-002 + trastuzumab + eribulin is an investigational **triple combination therapy** being evaluated for the treatment of **HER2-positive solid tumors**, including metastatic breast cancer. - **ELVN-002** is a selective and potent small molecule HER2 kinase inhibitor with a differentiated mechanism that drives increased HER2 receptor internalization and ubiquitination, reducing cell surface HER2 and potentially enhancing the anticancer activity of antibody-based and chemotherapeutic partners[3]. - **Trastuzumab** is a monoclonal antibody that targets the extracellular domain of the HER2 receptor, blocking downstream signaling and promoting antibody-dependent cellular cytotoxicity (ADCC)[1][4]. - **Eribulin** is a small molecule microtubule dynamics inhibitor in the halichondrin class, preventing cell division and causing apoptosis in cancer cells[1][2][4]. This combination is designed to exploit complementary mechanisms: blockade and degradation of HER2 signaling, enhanced receptor internalization, and cytotoxic cell death. Preclinical and early phase clinical studies indicate **additive effects** when combining ELVN-002 with trastuzumab and eribulin, with a focus on improved efficacy and manageable safety in HER2-expressing tumors[3][5].

Other names

ELVN-002 + trastuzumab + eribulin